Completed OBSERVATIONAL NCT00606528

FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy

Sponsor: University Health Network, Toronto

Conditions Chronic Hepatitis C Virus Infection

Updated 10 times since 2017 Last updated: Jul 24, 2013 Started: Feb 29, 2008 Primary completion: Jul 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Chronic Hepatitis C Virus Infection and is currently completed. University Health Network, Toronto leads this study, which shows 10 recorded versions since 2008 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Dec 2021 — Jul 2024 [monthly]

Completed
Jan 2021 — Dec 2021 [monthly]

Completed
Nov 2020 — Jan 2021 [monthly]

Completed

▶ Show 5 earlier versions

Jun 2018 — Nov 2020 [monthly]

Completed
May 2018 — Jun 2018 [monthly]

Completed
Apr 2018 — May 2018 [monthly]

Completed

Phase: NA → None
Aug 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Aug 2017 [monthly]

Completed NA

First recorded

Feb 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Health Network, Toronto

Data source: University Health Network, Toronto

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada